The latest cancer news, headlines and analysis from The NE Times.
The latest figures show the elective waiting list in England standing at more than 7.2 million cases, with progress on bringing it down described as sluggish and key cancer and emergency targets still being missed.
NHS England has announced that eligible men with early prostate cancer will be offered SABR, a targeted treatment that cuts the number of sessions from at least 20 to five.
Thousands of men with localised prostate cancer will be offered SABR, a high-precision radiotherapy that can be delivered in five sessions instead of 20 or more, after a £70 million investment in new machines across England.
Up to 400 women a year with hard-to-treat ovarian cancer will be offered mirvetuximab soravtansine, a targeted therapy shown to extend survival, after NICE recommended it for use on the NHS in England.